Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Rating) saw unusually-high trading volume on Monday . Approximately 54,657 shares changed hands during mid-day trading, a decline of 98% from the previous session’s volume of 2,638,332 shares.The stock last traded at $13.69 and had previously closed at $13.72.
Wall Street Analyst Weigh In
TAK has been the subject of a number of recent research reports. Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 19th. Jefferies Financial Group downgraded shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Finally, Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $21.00 to $24.00 in a report on Tuesday, July 19th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $24.00.
Takeda Pharmaceutical Stock Performance
The stock’s fifty day moving average price is $14.09 and its two-hundred day moving average price is $14.30. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.75 and a current ratio of 1.18. The company has a market cap of $41.43 billion, a P/E ratio of 25.21, a P/E/G ratio of 0.56 and a beta of 0.70.
Institutional Trading of Takeda Pharmaceutical
A number of institutional investors and hedge funds have recently made changes to their positions in TAK. First Republic Investment Management Inc. lifted its holdings in shares of Takeda Pharmaceutical by 17.1% during the 4th quarter. First Republic Investment Management Inc. now owns 35,142 shares of the company’s stock worth $479,000 after acquiring an additional 5,136 shares during the period. Dimensional Fund Advisors LP increased its position in Takeda Pharmaceutical by 37.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 117,449 shares of the company’s stock worth $1,601,000 after purchasing an additional 31,920 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Takeda Pharmaceutical by 534.5% during the 4th quarter. BNP Paribas Arbitrage SA now owns 273,002 shares of the company’s stock worth $3,721,000 after purchasing an additional 229,978 shares in the last quarter. Capital Fund Management S.A. acquired a new position in Takeda Pharmaceutical during the 4th quarter worth approximately $329,000. Finally, Qube Research & Technologies Ltd increased its position in Takeda Pharmaceutical by 3.8% during the 4th quarter. Qube Research & Technologies Ltd now owns 202,448 shares of the company’s stock worth $2,759,000 after purchasing an additional 7,368 shares in the last quarter. Institutional investors own 1.96% of the company’s stock.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.
- Get a free copy of the StockNews.com research report on Takeda Pharmaceutical (TAK)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.